NSCLC metastatic/molecular target

 
Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 21/06/2018)

EGFR
Currently no trials

ALK
LDK378-NIVOLUMAB (Novartis) -> for all lines
A multi-center, open-label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.


BFAST (Roche) -> for 1st line
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cance (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial).

KRAS
LXH254-LTT462 (Novartis) -> for 3th line and higher
A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer. 


RET
BFAST (Roche) -> for 1st line
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cance (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial).

BRAF
LXH254-LTT462 (Novartis) -> for 3th line and higher
A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer. 


C-MET
CINC280 (Novartis) -> for 1st, 2nd and 3th line
Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer
(only cohort 6 open)
 
New trial in start-up: currently no new trials